Partner with EsoCap

The EsoCap business model is to demonstrate technical functionality, clinical proof-of-concept in one clinical indication, eosinophilic esophagitis (EoE), industrial scale-up feasibility and then to enter into a sizable commercial transaction with a major pharmaceutical firm.
The EsoCap technology is a highly attractive partnering target for biopharmaceutical companies in many strategic areas, such as gastroenterology, immunology, oncology, orphan diseases, drug delivery, and CDMOs (contract development and manufacturing organisations).

If you are interested in investing or partnering with EsoCap AG, or would like to receive more information on our products and technology, please get in touch with us.